Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $232,349.00 in Stock

Posted by Geri Gentry on Jul 9th, 2026

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) CFO Raphi Levy sold 17,873 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $13.00, for a total value of $232,349.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,172,340. This trade represents a 16.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00.
On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00.
On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

NASDAQ DRTS opened at $12.78 on Thursday. The firm’s 50 day simple moving average is $10.15 and its 200 day simple moving average is $8.08. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -19.07 and a beta of 1.17. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical Ltd. has a 1 year low of $2.87 and a 1 year high of $14.11.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, research analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Barclays raised their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. LADENBURG THALM/SH SH raised their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 1st. Finally, Piper Sandler upped their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.60.

View Our Latest Stock Analysis on DRTS

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of DRTS. Daytona Street Capital LLC bought a new position in Alpha Tau Medical in the fourth quarter valued at about $749,000. Apella Capital LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $1,892,000. Mariner LLC grew its holdings in shares of Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after purchasing an additional 1,915 shares during the last quarter. Millennium Management LLC increased its stake in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares during the period. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.